<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jiang Q</submitter><funding>NCCIH NIH HHS</funding><pagination>20464-9</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2629323</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>105(51)</volume><pubmed_abstract>Cyclooxygenase (COX-1/COX-2)-catalyzed eicosanoid formation plays a key role in inflammation-associated diseases. Natural forms of vitamin E are recently shown to be metabolized to long-chain carboxychromanols and their sulfated counterparts. Here we find that vitamin E forms differentially inhibit COX-2-catalyzed prostaglandin E(2) in IL-1beta-stimulated A549 cells without affecting COX-2 expression, showing the relative potency of gamma-tocotrienol approximately delta-tocopherol > gamma-tocopherol >> alpha- or beta-tocopherol. The cellular inhibition is partially diminished by sesamin, which blocks the metabolism of vitamin E, suggesting that their metabolites may be inhibitory. Consistently, conditioned media enriched with long-chain carboxychromanols, but not their sulfated counterparts or vitamin E, reduce COX-2 activity in COX-preinduced cells with 5 microM arachidonic acid as substrate. Under this condition, 9'- or 13'-carboxychromanol, the vitamin E metabolites that contain a chromanol linked with a 9- or 13-carbon-length carboxylated side chain, inhibits COX-2 with an IC(50) of 6 or 4 microM, respectively. But 13'-carboxychromanol inhibits purified COX-1 and COX-2 much more potently than shorter side-chain analogs or vitamin E forms by competitively inhibiting their cyclooxygenase activity with K(i) of 3.9 and 10.7 microM, respectively, without affecting the peroxidase activity. Computer simulation consistently indicates that 13'-carboxychromanol binds more strongly than 9'-carboxychromanol to the substrate-binding site of COX-1. Therefore, long-chain carboxychromanols, including 13'-carboxychromanol, are novel cyclooxygenase inhibitors, may serve as anti-inflammation and anticancer agents, and may contribute to the beneficial effects of certain forms of vitamin E.</pubmed_abstract><journal>Proceedings of the National Academy of Sciences of the United States of America</journal><pubmed_title>Long-chain carboxychromanols, metabolites of vitamin E, are potent inhibitors of cyclooxygenases.</pubmed_title><pmcid>PMC2629323</pmcid><funding_grant_id>P01AT002620</funding_grant_id><funding_grant_id>R01 AT001821</funding_grant_id><funding_grant_id>R01AT001821</funding_grant_id><funding_grant_id>P01 AT002620</funding_grant_id><pubmed_authors>Yin X</pubmed_authors><pubmed_authors>Huang J</pubmed_authors><pubmed_authors>Danielson ML</pubmed_authors><pubmed_authors>Jiang Q</pubmed_authors><pubmed_authors>Freiser H</pubmed_authors><pubmed_authors>Lill MA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Long-chain carboxychromanols, metabolites of vitamin E, are potent inhibitors of cyclooxygenases.</name><description>Cyclooxygenase (COX-1/COX-2)-catalyzed eicosanoid formation plays a key role in inflammation-associated diseases. Natural forms of vitamin E are recently shown to be metabolized to long-chain carboxychromanols and their sulfated counterparts. Here we find that vitamin E forms differentially inhibit COX-2-catalyzed prostaglandin E(2) in IL-1beta-stimulated A549 cells without affecting COX-2 expression, showing the relative potency of gamma-tocotrienol approximately delta-tocopherol > gamma-tocopherol >> alpha- or beta-tocopherol. The cellular inhibition is partially diminished by sesamin, which blocks the metabolism of vitamin E, suggesting that their metabolites may be inhibitory. Consistently, conditioned media enriched with long-chain carboxychromanols, but not their sulfated counterparts or vitamin E, reduce COX-2 activity in COX-preinduced cells with 5 microM arachidonic acid as substrate. Under this condition, 9'- or 13'-carboxychromanol, the vitamin E metabolites that contain a chromanol linked with a 9- or 13-carbon-length carboxylated side chain, inhibits COX-2 with an IC(50) of 6 or 4 microM, respectively. But 13'-carboxychromanol inhibits purified COX-1 and COX-2 much more potently than shorter side-chain analogs or vitamin E forms by competitively inhibiting their cyclooxygenase activity with K(i) of 3.9 and 10.7 microM, respectively, without affecting the peroxidase activity. Computer simulation consistently indicates that 13'-carboxychromanol binds more strongly than 9'-carboxychromanol to the substrate-binding site of COX-1. Therefore, long-chain carboxychromanols, including 13'-carboxychromanol, are novel cyclooxygenase inhibitors, may serve as anti-inflammation and anticancer agents, and may contribute to the beneficial effects of certain forms of vitamin E.</description><dates><release>2008-01-01T00:00:00Z</release><publication>2008 Dec</publication><modification>2024-11-14T04:17:18.98Z</modification><creation>2019-03-27T00:20:19Z</creation></dates><accession>S-EPMC2629323</accession><cross_references><pubmed>19074288</pubmed><doi>10.1073/pnas.0810962106</doi></cross_references></HashMap>